Journal of Antimicrobial Chemotherapy (1999) 43, 569-573
© 1999 The British Society for Antimicrobial Chemotherapy
Brief report |
Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci
Institute of Medical Microbiology, Westfälische Wilhelms-Universität Münster, Domagkstraße 10, 48149 Münster, Germany
The antistaphylococcal activities of four newly developed antibiotics, moxifloxacin (an 8-methoxyfluoroquinolone), trovafloxacin (a naphthyridone), quinupristin/dalfopristin (a semisynthetic streptogramin) and linezolid (an oxazolidinone), were examined and compared with those of ciprofloxacin, vancomycin and teicoplanin, using an agar dilution method. A total of 245 clinical isolates of staphylococci, including a large number of clonally different methicillin-resistant strains, were tested. The new agents tested exhibited wide-spectrum antistaphylococcal activity against both methicillin-susceptible and methicillin-resistant strains. In contrast to the quinolones, the in-vitro activities of quinupristin/dalfopristin, linezolid and the glycopeptides remained almost unchanged, irrespective of the resistance phenotype for methicillin. A number of isolates with elevated quinolone MICs were observed.
Corresponding author. Tel: +59-251-835-5360; Fax: +49-251-835-5350; E-mail: eiffc{at}uni-muester.de
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Abe, K. Chiba, B. Cirincione, T. H. Grasela, K. Ito, and T. Suwa Population Pharmacokinetic Analysis of Linezolid in Patients With Infectious Disease: Application to Lower Body Weight and Elderly Patients J. Clin. Pharmacol., September 1, 2009; 49(9): 1071 - 1078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Malincarne, M. Ghebregzabher, M. V. Moretti, A. M. Egidi, B. Canovari, G. Tavolieri, D. Francisci, G. Cerulli, and F. Baldelli Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty J. Antimicrob. Chemother., May 1, 2006; 57(5): 950 - 954. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. von Eiff, A. W. Friedrich, K. Becker, and G. Peters Comparative In Vitro Activity of Ceftobiprole against Staphylococci Displaying Normal and Small-Colony Variant Phenotypes Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4372 - 4374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Stalker, G. L. Jungbluth, N. K. Hopkins, and D. H. Batts Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers J. Antimicrob. Chemother., May 1, 2003; 51(5): 1239 - 1246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ince, X. Zhang, and D. C. Hooper Activity of and Resistance to Moxifloxacin in Staphylococcus aureus Antimicrob. Agents Chemother., April 1, 2003; 47(4): 1410 - 1415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gander, K. Hayward, and R. Finch An investigation of the antimicrobial effects of linezolid on bacterial biofilms utilizing an in vitro pharmacokinetic model J. Antimicrob. Chemother., February 1, 2002; 49(2): 301 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Betriu, M. Redondo, A. Boloix, M. Gomez, E. Culebras, and J. J. Picazo Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci J. Antimicrob. Chemother., December 1, 2001; 48(6): 911 - 913. [Abstract] [Full Text] [PDF]
|
|